Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Myeloproliferative Disorders 1Myeloid Malignancies 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 29Bevacizumab 12Radiotherapy 10Irinotecan 7Carboplatin 7Carmustine 5Magnetic Resonance Spectroscopy 4Filgrastim 4Cyclophosphamide 4Cisplatin 4Vincristine 3Thiotepa 3Surgical Procedures, Operative 3Peripheral Blood Stem Cell Transplantation 3Etoposide 3talampanel 2sargramostim 2antineoplaston AS 2-1 2antineoplaston A10 2abemaciclib 2Topotecan 2Thalidomide 2Tamoxifen 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Procarbazine 2Immunoglobulin G 2Everolimus 2Drug Therapy 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Oligodendroglioma × olutasidenib × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡